Facing a real person: an event-related potential study.

Neuroreport

Human Information Processing Laboratory, Department of Psychology, University of Tampere, Tampere, Finland.

Published: March 2008

Although faces are typically perceived in the context of human interaction, face processing is commonly studied by displaying faces on a computer screen. This study on event-related potential examined whether the processing of faces differs depending on whether participants are viewing faces live or on a computer screen. In both the conditions, the participants were shown a real face, a dummy face, and a control object. N170 and early posterior negativity discriminated between faces and control object in both the conditions. Interestingly, early posterior negativity differentiated between the real face and the dummy face only in the live condition. The results indicate that a live face, as a potentially interacting stimulus, is processed differently than an inanimate face already at the early processing stages.

Download full-text PDF

Source
http://dx.doi.org/10.1097/WNR.0b013e3282f7c4d3DOI Listing

Publication Analysis

Top Keywords

event-related potential
8
computer screen
8
real face
8
face dummy
8
dummy face
8
control object
8
early posterior
8
posterior negativity
8
face
7
faces
5

Similar Publications

Visual narratives, like comics, at times show depictions of characters' imagination, dreams, or flashbacks, which seem incongruent with the ongoing primary narrative. Such "domain constructions" thus integrate an auxiliary domain (e.g.

View Article and Find Full Text PDF

Background: The PanaMa trial aimed to compare the efficacy of 5-fluorouracil and folinic acid (FU/FA) ± panitumumab maintenance in untreated wild-type metastatic colorectal cancer (mCRC) patients.

Methods: In this final phase 2 trial analysis, adult mCRC patients responding to six cycles of FU/FA, oxaliplatin and panitumumab were randomized (1:1, open-label) to maintenance of either FU/FA + panitumumab or FU/FA alone. The primary endpoint was superiority of progression-free survival of maintenance (PFS; time from random assignment to progression/death) in favour of FU/FA + panitumumab.

View Article and Find Full Text PDF

Unveiling unexpected adverse events: post-marketing safety surveillance of gilteritinib and midostaurin from the FDA Adverse Event Reporting database.

Ther Adv Drug Saf

January 2025

Department of Pharmacy, Daping Hospital, Army Medical University, No. 10 Changjiang Branch Road, Yuzhong District, Chongqing 400042, China.

Background: Gilteritinib and midostaurin are FLT3 inhibitors that have made significant progress in the treatment of acute myeloid leukemia. However, their real-world safety profile in a large sample population is incomplete.

Objectives: We aimed to provide a pharmacovigilance study of the adverse events (AEs) associated with gilteritinib and midostaurin through the Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) database.

View Article and Find Full Text PDF

Brainprint recognition technology, regarded as a promising biometric technology, encounters challenges stemming from the time-varied, low signal-to-noise ratio of brain signals, such as electroencephalogram (EEG). Steady-state visual evoked potentials (SSVEP) exhibit high signal-to-noise ratio and frequency locking, making them a promising paradigm for brainprint recognition. Consequently, the extraction of time-invariant identity information from SSVEP EEG signals is essential.

View Article and Find Full Text PDF

Objectives: A combination of chemotherapy and radiotherapy is employed in the curative and postoperative treatment of locally advanced head and neck cancers (HNC). Integrated chemoradiation (CRT) treatments result in a non-negligible rate of severe toxic effects. Treatment-related death (TRD) is a crucial topic for physicians involved in the curative treatment of HNC.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!